tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Erasca (ERAS)
NASDAQ:ERAS
US Market
ERAS
Erasca
RESEARCH TOOLSreports

Erasca (ERAS) Stock News & Sentiment

Compare
316 Followers
Erasca Highlights Accelerated Progress in RAS-Targeted Trials
Premium
Company Announcements
Erasca Highlights Accelerated Progress in RAS-Targeted Trials
1d ago
8K
ERAS
Erasca, Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Erasca, Inc. Reports Q3 2025 Financial Results
2M ago
ERAS
Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001
Premium
Company Announcements
Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001
3M ago
ERAS
Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study
Premium
Company Announcements
Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study
3M ago
ERAS
Erasca’s SEACRAFT-2 Study: A Promising Step in Melanoma Treatment
Premium
Company Announcements
Erasca’s SEACRAFT-2 Study: A Promising Step in Melanoma Treatment
3M ago
ERAS
Erasca’s Strategic Positioning and Growth Potential in the RAS Inhibitor Market: Analyst Recommends ‘Buy’ with $4 Price Target
Premium
Ratings
Erasca’s Strategic Positioning and Growth Potential in the RAS Inhibitor Market: Analyst Recommends ‘Buy’ with $4 Price Target
3M ago
ERAS
Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
Premium
Ratings
Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
5M ago
ERAS
More ERAS News >

ERAS News on the Web

Why Erasca, Inc.’s (ERAS) Stock Is Up 9.95%
AAII
Neutral
Erasca’s Early Clinical Progress Signals Potential Breakthroughs in RAS-Targeting Cancer Therapies
Market Chameleon
Neutral
Why Erasca, Inc.’s (ERAS) Stock Is Down 6.92%
AAII
Neutral
Erasca to Spotlight Oncology Pipeline at J.P. Morgan Healthcare Conference—Investor Attention Turns to RAS/MAPK Strategy
Market Chameleon
Neutral
Erasca to Spotlight RAS/MAPK Cancer Therapies at 44th Annual J.P. Morgan Healthcare Conference
Market Chameleon
Neutral
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.30%
AAII
Neutral
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.07%
AAII
Neutral
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.07%
AAII
Neutral

News Score - Last 7 Days

Neutral
ERAS
Sector Average
Media Buzz
This Week4 articles
Weekly Average2 articles
News Sentiment
This Week50%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ERAS’s Media Buzz Sentiment?
4 articles about ERAS were published this week. In an average week, 2 articles are published.
    What is ERAS’s weekly average amount of articles?
    In an average week, 2 articles about ERAS are published.
      What is ERAS’s News Sentiment?
      50% of articles about ERAS were positive this week, compared to its sector average of 58%.
        Healthcare Stocks that are Trending in the News
        KRYSKrystal Biotech
        RVMDRevolution Medicines
        ANSLFAnsell
        RPRXRoyalty Pharma
        GLUEMonte Rosa Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week